Protagenic Therapeutics/$PTIX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Protagenic Therapeutics
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's main compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.
Ticker
$PTIX
Sector
Primary listing
Employees
2
Headquarters
Website
PTIX Metrics
BasicAdvanced
$2.1M
-
-$13.05
0.38
-
Price and volume
Market cap
$2.1M
Beta
0.38
52-week high
$14.28
52-week low
$2.35
Average daily volume
3.7M
Financial strength
Current ratio
0.862
Quick ratio
0.811
Profitability
EBITDA (TTM)
-5.36
Management effectiveness
Return on assets (TTM)
-189.60%
Return on equity (TTM)
-512.79%
Valuation
Price to book
-22.21
Price to tangible book (TTM)
-22.21
Price to free cash flow (TTM)
-0.404
Free cash flow yield (TTM)
-247.33%
Free cash flow per share (TTM)
-9.027
Growth
Earnings per share change (TTM)
-32.12%
3-year earnings per share growth (CAGR)
-6.48%
PTIX News
AllArticlesVideos
Protagenic Therapeutics Provides Update on Form 10-Q Filing Timeline and Nasdaq Compliance
Accesswire·20 hours ago
Protagenic Therapeutics Advances PT00114 into Multiple-Dose Phase 1 Trial; Positioning for Phase 2 in Stress & Mood Disorders
Accesswire·2 days ago
Protagenic Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid Program Drug Candidates
MCAP MediaWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Protagenic Therapeutics stock?
Protagenic Therapeutics (PTIX) has a market cap of $2.1M as of August 23, 2025.
What is the P/E ratio for Protagenic Therapeutics stock?
The price to earnings (P/E) ratio for Protagenic Therapeutics (PTIX) stock is 0 as of August 23, 2025.
Does Protagenic Therapeutics stock pay dividends?
No, Protagenic Therapeutics (PTIX) stock does not pay dividends to its shareholders as of August 23, 2025.
When is the next Protagenic Therapeutics dividend payment date?
Protagenic Therapeutics (PTIX) stock does not pay dividends to its shareholders.
What is the beta indicator for Protagenic Therapeutics?
Protagenic Therapeutics (PTIX) has a beta rating of 0.38. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.